24 Jul
2013
24 Jul
'13
7:49 p.m.
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and to
be able to thank all of you for your contributions. We wouldn't be here
without the hard work from all of you, the huge pool of scientific
expertise and insight, and the collaborative spirit that we've had in
this project. Please pass my thanks also to technicians and other
members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope
that this will inspire many other collaborations amongst us. I had a lot
of fun and I hope you did too! But the most important thing is that I
think we can all be proud of the outcome. It's a great paper and a great
data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in
touch about press releases, publication and embargo dates, etc. when we
know more. Feel free to share the news with close colleagues, but please
don't advertise this yet in the public domain such as social media. The
companions papers are in a good shape too: we're waiting for the final
confirmation of the acceptance of the QC paper in Nature Biotechnology
so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work
for much longer (in case you didn't know, I'm spending this year at
Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
24 Jul
24 Jul
7:54 p.m.
Dear Tuuli
That is excellent news! Needless to say that I am extremely happy with the outcome and I
enjoyed the collaborative work a lot.
You deserve a statue for your enormous drive, perseverence and creativity.
I hope to hear from Nature Biotech very soon.
Best
Peter
________________________________________
From: Tuuli Lappalainen [tuuli.e.lappalainen(a)gmail.com]
Sent: Wednesday, July 24, 2013 7:49 PM
To: geuvadis_rnaseq(a)lists.crg.es; geuvadis_wpl(a)lists.crg.es
Cc: Manolis Dermitzakis; Oliver Stegle; Helena Kilpinen; M.Sammeth;
marc.friedlaender(a)crg.eu; Hoen, P.A.C. 't (HG); Jean Monlong; Manuel Rivas; Mar
Gonzàlez Porta; Natalja Kurbatova; Thasso Griebel; Pedro Gabriel Ferreira; Matthias
Barann; Thomas Wieland; Liliana Greger; Maarten van Iterson; Jonas Carlsson; Paolo Ribeca;
Pulyakhina, I. (HG); Daniela Esser; Thomas Giger; andrew(a)ebi.ac.uk; Marc Sultan; Gabrielle
Anne Bertier; Daniel MacArthur; Monkol Lek; Esther Lizano; Buermans, H.P.J. (HG); Ismael
Padioleau; Tim M Strom; Thomas Schwarzmayr; Olof Karlberg; halit.ongen(a)unige.ch; Sergi
Beltran Agulló; Marta Gut; Vyacheslav Amstislavskiy; Stephen Montgomery; Mark McCarthy;
Paul Flicek; lehrach(a)molgen.mpg.de; Stefan Schreiber; Ralf Sudbrak;
angel.carracedo(a)usc.es; Stylianos ANTONARAKIS; r.haesler(a)mucosa.de; Ann-Christine Syvänen;
Ommen, G.J.B. van (HG); Alvis Brazma; ?meitinger(a)helmholtz-muenchen.de; Philip Rosenstiel;
Roderic Guigo; Ivo Gut; Xavier Estivill; geuvadis_rna_analysis(a)lists.crg.es
Subject: Geuvadis RNAseq paper accepted in Nature
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and to
be able to thank all of you for your contributions. We wouldn't be here
without the hard work from all of you, the huge pool of scientific
expertise and insight, and the collaborative spirit that we've had in
this project. Please pass my thanks also to technicians and other
members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope
that this will inspire many other collaborations amongst us. I had a lot
of fun and I hope you did too! But the most important thing is that I
think we can all be proud of the outcome. It's a great paper and a great
data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in
touch about press releases, publication and embargo dates, etc. when we
know more. Feel free to share the news with close colleagues, but please
don't advertise this yet in the public domain such as social media. The
companions papers are in a good shape too: we're waiting for the final
confirmation of the acceptance of the QC paper in Nature Biotechnology
so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work
for much longer (in case you didn't know, I'm spending this year at
Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
7:55 p.m.
Dear all
Let me thank you all for your hard work and Tuuli in particular for being an outstanding
driver!
It has been a bumpy but very rewarding experience! Congratulations to all!
Enjoy this outcome and let's hope for new and exciting collaborations
Best
Manolis
Sent from my iPhone
On 24 juil. 2013, at 20:49, "Tuuli Lappalainen"
<tuuli.e.lappalainen(a)gmail.com> wrote:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has been accepted in
Nature!
Needless to say, I'm extremely happy to finally be at this point, and to be able to
thank all of you for your contributions. We wouldn't be here without the hard work
from all of you, the huge pool of scientific expertise and insight, and the collaborative
spirit that we've had in this project. Please pass my thanks also to technicians and
other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope that this will
inspire many other collaborations amongst us. I had a lot of fun and I hope you did too!
But the most important thing is that I think we can all be proud of the outcome. It's
a great paper and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in touch about
press releases, publication and embargo dates, etc. when we know more. Feel free to share
the news with close colleagues, but please don't advertise this yet in the public
domain such as social media. The companions papers are in a good shape too: we're
waiting for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work for much longer
(in case you didn't know, I'm spending this year at Stanford). Please use
tuuli.e.lappalainen(a)gmail.com for future correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
8:09 p.m.
Dear Tuuli, Manolis and all,
Congratulations for a fantastic outcome of this geuvadis project!
All the best to everyone!
Xavier
El 24/07/2013, a les 19:55, Emmanouil Dermitzakis va escriure:
Dear all
Let me thank you all for your hard work and Tuuli in particular for being an outstanding
driver!
It has been a bumpy but very rewarding experience! Congratulations to all!
Enjoy this outcome and let's hope for new and exciting collaborations
Best
Manolis
Sent from my iPhone
On 24 juil. 2013, at 20:49, "Tuuli Lappalainen"
<tuuli.e.lappalainen(a)gmail.com> wrote:
> Dear all,
>
> It is my great pleasure to tell you that the Geuvadis RNAseq paper has been accepted
in Nature!
>
> Needless to say, I'm extremely happy to finally be at this point, and to be able
to thank all of you for your contributions. We wouldn't be here without the hard work
from all of you, the huge pool of scientific expertise and insight, and the collaborative
spirit that we've had in this project. Please pass my thanks also to technicians and
other members of your lab who contributed to this work.
>
> It was a really enjoyable experience to work with all of you, and I hope that this
will inspire many other collaborations amongst us. I had a lot of fun and I hope you did
too! But the most important thing is that I think we can all be proud of the outcome.
It's a great paper and a great data set that make an important contribution to the
field.
>
> We're now going through some final formatting edits, and we'll be in touch
about press releases, publication and embargo dates, etc. when we know more. Feel free to
share the news with close colleagues, but please don't advertise this yet in the
public domain such as social media. The companions papers are in a good shape too:
we're waiting for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is under review in
Genome Research.
>
>
> best regards,
> Tuuli
>
> PS. Please note that my University of Geneva email address will not work for much
longer (in case you didn't know, I'm spending this year at Stanford). Please use
tuuli.e.lappalainen(a)gmail.com for future correspondence.
>
>
> --
> Tuuli Lappalainen, PhD
> Department of Genetics, Stanford University School of Medicine
> Email: tuuli.e.lappalainen(a)gmail.com
> Tel: +1 415 351 9713
> Bustamante lab
> Department of Genetics
> 300 Pasteur Dr. Lane L301
> Stanford, CA 94305-5120
> USA
>
7:57 p.m.
Fantastic news!! Congratulations!
Manny
On Wed, Jul 24, 2013 at 6:49 PM, Tuuli Lappalainen <
tuuli.e.lappalainen(a)gmail.com> wrote:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and to
be able to thank all of you for your contributions. We wouldn't be here
without the hard work from all of you, the huge pool of scientific
expertise and insight, and the collaborative spirit that we've had in this
project. Please pass my thanks also to technicians and other members of
your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope
that this will inspire many other collaborations amongst us. I had a lot of
fun and I hope you did too! But the most important thing is that I think we
can all be proud of the outcome. It's a great paper and a great data set
that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in touch
about press releases, publication and embargo dates, etc. when we know
more. Feel free to share the news with close colleagues, but please don't
advertise this yet in the public domain such as social media. The
companions papers are in a good shape too: we're waiting for the final
confirmation of the acceptance of the QC paper in Nature Biotechnology so
more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work
for much longer (in case you didn't know, I'm spending this year at
Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
8:06 p.m.
Great. Thanks a lot Tuuli for the persistent effort!
R
Fantastic news!! Congratulations!
Manny
On Wed, Jul 24, 2013 at 6:49 PM, Tuuli Lappalainen
<tuuli.e.lappalainen(a)gmail.com <mailto:tuuli.e.lappalainen@gmail.com>>
wrote:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper
has been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point,
and to be able to thank all of you for your contributions. We
wouldn't be here without the hard work from all of you, the huge
pool of scientific expertise and insight, and the collaborative
spirit that we've had in this project. Please pass my thanks also
to technicians and other members of your lab who contributed to
this work.
It was a really enjoyable experience to work with all of you, and
I hope that this will inspire many other collaborations amongst
us. I had a lot of fun and I hope you did too! But the most
important thing is that I think we can all be proud of the
outcome. It's a great paper and a great data set that make an
important contribution to the field.
We're now going through some final formatting edits, and we'll be
in touch about press releases, publication and embargo dates, etc.
when we know more. Feel free to share the news with close
colleagues, but please don't advertise this yet in the public
domain such as social media. The companions papers are in a good
shape too: we're waiting for the final confirmation of the
acceptance of the QC paper in Nature Biotechnology so more good
news will follow, and the splicing paper is under review in Genome
Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will
not work for much longer (in case you didn't know, I'm spending
this year at Stanford). Please use tuuli.e.lappalainen(a)gmail.com
<mailto:tuuli.e.lappalainen@gmail.com> for future correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
<mailto:tuuli.e.lappalainen@gmail.com>
Tel: +1 415 351 9713 <tel:%2B1%20415%20351%209713>
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
.
--
(1) Centre de Regulacio Genomica
(2) Universitat Pompeu Fabra
Dr. Aiguader, 88 +34 93 3160110 ph
E-08003 Barcelona +34 93 3969983 fax
email: roderic.guigo(a)crg.cat http://big.crg.cat
CRG/"la Caixa" PhD FELLOWSHIPS, http://www.crg.eu/lacaixa_fellowships
REGISTRATION DEADLINE: 28th February, 2013
8:15 p.m.
Great news, this is awesome, well deserved and will be an important contribution for the
Community !
Best, Philip
Sent from my mobile, apologies for typos.
Am 24.07.2013 um 19:49 schrieb "Tuuli Lappalainen"
<tuuli.e.lappalainen(a)gmail.com>om>:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and to
be able to thank all of you for your contributions. We wouldn't be here
without the hard work from all of you, the huge pool of scientific
expertise and insight, and the collaborative spirit that we've had in
this project. Please pass my thanks also to technicians and other
members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope
that this will inspire many other collaborations amongst us. I had a lot
of fun and I hope you did too! But the most important thing is that I
think we can all be proud of the outcome. It's a great paper and a great
data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in
touch about press releases, publication and embargo dates, etc. when we
know more. Feel free to share the news with close colleagues, but please
don't advertise this yet in the public domain such as social media. The
companions papers are in a good shape too: we're waiting for the final
confirmation of the acceptance of the QC paper in Nature Biotechnology
so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work
for much longer (in case you didn't know, I'm spending this year at
Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
10:13 p.m.
Congratulations. This is a substantial achievement and it is well deserved.
Kind regards
Stefan
Von meinem iPad gesendet
Am 24.07.2013 um 19:49 schrieb Tuuli Lappalainen <tuuli.e.lappalainen(a)gmail.com>om>:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has been accepted in
Nature!
Needless to say, I'm extremely happy to finally be at this point, and to be able to
thank all of you for your contributions. We wouldn't be here without the hard work
from all of you, the huge pool of scientific expertise and insight, and the collaborative
spirit that we've had in this project. Please pass my thanks also to technicians and
other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope that this will
inspire many other collaborations amongst us. I had a lot of fun and I hope you did too!
But the most important thing is that I think we can all be proud of the outcome. It's
a great paper and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in touch about
press releases, publication and embargo dates, etc. when we know more. Feel free to share
the news with close colleagues, but please don't advertise this yet in the public
domain such as social media. The companions papers are in a good shape too: we're
waiting for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work for much longer
(in case you didn't know, I'm spending this year at Stanford). Please use
tuuli.e.lappalainen(a)gmail.com for future correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
25 Jul
25 Jul
8:27 a.m.
New subject: [Geuvadis_rna_analysis] [Geuvadis_rnaseq] Geuvadis RNAseq paper accepted in Nature
Congratulations Tuuli and everyone ! What an achievement !
All the best,
Gabrielle
Am 24.07.2013 um 19:49 schrieb Tuuli Lappalainen <tuuli.e.lappalainen(a)gmail.com>om>:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has been accepted in
Nature!
Needless to say, I'm extremely happy to finally be at this point, and to be able to
thank all of you for your contributions. We wouldn't be here without the hard work
from all of you, the huge pool of scientific expertise and insight, and the collaborative
spirit that we've had in this project. Please pass my thanks also to technicians and
other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I hope that this will
inspire many other collaborations amongst us. I had a lot of fun and I hope you did too!
But the most important thing is that I think we can all be proud of the outcome. It's
a great paper and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in touch about
press releases, publication and embargo dates, etc. when we know more. Feel free to share
the news with close colleagues, but please don't advertise this yet in the public
domain such as social media. The companions papers are in a good shape too: we're
waiting for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is under review in
Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not work for much longer
(in case you didn't know, I'm spending this year at Stanford). Please use
tuuli.e.lappalainen(a)gmail.com for future correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
_______________________________________________
Geuvadis_rnaseq mailing list
Geuvadis_rnaseq(a)lists.crg.es
http://davinci.crg.es/mailman/listinfo/geuvadis_rnaseq
10:13 a.m.
Dear Tuuli,
excellent job and excellent news. Many thanks to all the effort you put
into this project.
Best wishes
Ralf
Am 24.07.13 19:49, schrieb Tuuli Lappalainen:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and
to be able to thank all of you for your contributions. We wouldn't be
here without the hard work from all of you, the huge pool of
scientific expertise and insight, and the collaborative spirit that
we've had in this project. Please pass my thanks also to technicians
and other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I
hope that this will inspire many other collaborations amongst us. I
had a lot of fun and I hope you did too! But the most important thing
is that I think we can all be proud of the outcome. It's a great paper
and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in
touch about press releases, publication and embargo dates, etc. when
we know more. Feel free to share the news with close colleagues, but
please don't advertise this yet in the public domain such as social
media. The companions papers are in a good shape too: we're waiting
for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is
under review in Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not
work for much longer (in case you didn't know, I'm spending this year
at Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
9 Sep
9 Sep
6:44 p.m.
New subject: [Geuvadis_rna_analysis] Geuvadis RNAseq Nature paper online publication
Dear all,
The Geuvadis RNAseq Nature paper has been scheduled for advance online
publication on September 15 at 1800 London time, 1900 CET, which is the
time the embargo is lifted.
A couple of points about the media strategy:
- The international press release: we're coordinating this together with
UNIGE and EBI/EMBL press offices
- Local press releases: those of you who are planning to send out a
local PR, please make sure that: 1) your press office receives the
instructions from the Nature press office (copypasted below) and the
embargo is respected, 2) your press release is distributed only
nationally, and 3) you send a copy of your press release to me, Manolis
and Gabrielle.
- Social media: after the embargo is lifted, you're free (and
encouraged) to advertise the paper on twitter, facebook, your
website/blog, etc. On twitter, please use hashtag #geuvadis; I'll be
posting under @tuuliel.
- If you come across any substantial criticism or questions regarding
the paper in the blogosphere or elsewhere, please let me and Manolis
know so that we can formulate a response together.
best regards,
Tuuli
Your paper 'Transcriptome and genome sequencing uncovers functional
variation in humans' has been *scheduled for Advance Online Publication
(AOP) on http://www.nature.com/nature <http://www.nature.com/nature> on
15 September 2013 at 1800 London time / 1300 US Eastern Time*. The
embargo will lift at this time. Please forward this information to any
co-authors.
Papers published online before they have been allocated to a print issue
will be citable via a digital object identifier (DOI) number. The DOI
for your paper will be 10.1038/nature12531. Once the paper is published
electronically, the DOI can be used to retrieve the abstract and full
text from the /Nature/ web site (abstracts are available to everyone,
full text only to subscribers) by adding it to the following URL:
http://dx.doi.org/ .
On the Tuesday before publication, /Nature/ distributes a press release
highlighting papers of general interest. Journalists are given the name
of the author(s) to contact, together with phone numbers and e-mail
addresses. Journalists are also given online access not only to the
papers on the press release but to all the papers due to appear in that
issue. This means that your work could well receive media interest even
if not featured on the press release, so it would be helpful if you (as
corresponding author, we would, as a matter of course, put your name and
affiliation on our press release as a contact, and attribute the work to
you plus colleagues, so please let me know if this would not be
appropriate) or a colleague could be available to answer any inquiries
in the days leading up to publication.
You are free to discuss your paper with the media, but we ask you to do
this no more than five days before the publication date, and to ensure
that /Nature's/ embargo conditions are understood by journalists and
others. /Nature/ reserves the right to halt the publication of a paper
if these conditions are broken. Journalists are permitted to show papers
to independent specialists a few days in advance of publication, under
embargo conditions, solely for the purpose of commenting on the work
described.
Wire services stories must always carry the embargo time at the head of
each item, and may not be sent out more than 24 hours before that time.
Journalists should credit /Nature/ as the source of stories covered.
If you need further clarification about anything related to publicity,
please contact one of the /Nature/ offices, as indicated below:
/For North America and Canada/
Neda Afsarmanesh (/Nature/, New York)
Tel: +1 212 726 9231; E-mail: n.afsarmanesh(a)us.nature.com
<mailto:n.afsarmanesh@us.nature.com>
/For Japan, Korea, China, Singapore and Taiwan/
Eiji Matsuda (/Nature/, Tokyo)
Tel: +81 3 3267 8751; E-mail: e.matsuda(a)natureasia.com
<mailto:e.matsuda@natureasia.com>
/For the UK/
Rebecca Walton (/Nature/, London)
Tel: +44 20 7843 4502; E-mail: r.walton(a)nature.com
<mailto:r.walton@nature.com>
Rachel Twinn (/Nature/, London)
Tel: +44 20 7843 4658; E-mail: r.twinn(a)nature.com
<mailto:r.twinn@nature.com>
If you are reporting sequence or structural data with an accession code
for a public database, we request you to set the release into the public
domain upon receipt of this letter. This will allow our editors to test
the link from the journal website to the database in readiness for the
date of publication of your article. For authors reporting protein
structures, release of the coordinates now will also allow us to set up
a three-dimensional view window within the online version of the article.
For any queries concerning proofs or corrections, please contact the
Editorial Production department in London.
You and your coauthors, or your institutions, can also order copies of
the issue of /Nature/ containing your article: please contact
g.painter(a)nature.com <mailto:g.painter@nature.com>, stating the
publication reference and the number of copies required.
If you and your coauthors are not subscribers to /Nature/ and would like
to subscribe, please contact subscriptions(a)nature.com and ask for
details of special prices for published /Nature/ authors.
On /24/713 10:49 AM, Tuuli Lappalainen wrote:
Dear all,
It is my great pleasure to tell you that the Geuvadis RNAseq paper has
been accepted in Nature!
Needless to say, I'm extremely happy to finally be at this point, and
to be able to thank all of you for your contributions. We wouldn't be
here without the hard work from all of you, the huge pool of
scientific expertise and insight, and the collaborative spirit that
we've had in this project. Please pass my thanks also to technicians
and other members of your lab who contributed to this work.
It was a really enjoyable experience to work with all of you, and I
hope that this will inspire many other collaborations amongst us. I
had a lot of fun and I hope you did too! But the most important thing
is that I think we can all be proud of the outcome. It's a great paper
and a great data set that make an important contribution to the field.
We're now going through some final formatting edits, and we'll be in
touch about press releases, publication and embargo dates, etc. when
we know more. Feel free to share the news with close colleagues, but
please don't advertise this yet in the public domain such as social
media. The companions papers are in a good shape too: we're waiting
for the final confirmation of the acceptance of the QC paper in Nature
Biotechnology so more good news will follow, and the splicing paper is
under review in Genome Research.
best regards,
Tuuli
PS. Please note that my University of Geneva email address will not
work for much longer (in case you didn't know, I'm spending this year
at Stanford). Please use tuuli.e.lappalainen(a)gmail.com for future
correspondence.
--
Tuuli Lappalainen, PhD
Department of Genetics, Stanford University School of Medicine
Email: tuuli.e.lappalainen(a)gmail.com
Tel: +1 415 351 9713
Bustamante lab
Department of Genetics
300 Pasteur Dr. Lane L301
Stanford, CA 94305-5120
USA
4057
days inactive
4104
days old
geuvadis_rna_analysis@lists.crg.es
10 comments
10 participants
participants (10)
-
Emmanouil Dermitzakis -
Gabrielle Anne Bertier -
Manuel Rivas -
P.A.C._t_Hoen＠lumc.nl -
Ralf Sudbrak -
Roderic Guigo -
Rosenstiel, Philip -
Stefan Schreiber -
Tuuli Lappalainen -
Xavier Estivill